Lingvay, I., Armstrong, M
Tirzepatide has documented improvements in blood pressure, lipids, and other cardiometabolic parameters across its phase 3 program, consistent with its degree of weight loss, and cardiovascular outcome data continue to accumulate
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Working in concert with GLP-1, GIP activation further augments insulin release and contributes to feelings of satiety
the fact that the Companys product candidates may cause serious adverse events or undesirable side effects or have other properties that may cause it to suspend or discontinue clinical studies, delay or prevent regulatory development, prevent their regulatory approval, limit the commercial profile, or result in significant negative consequences
The meta-analyses in this age group show clear benefits for lean mass preservation and functional strength